Modern epigenetics methods in biological research is a research paper published in Methods (2020). On theSindex it has a DataRank of 5.0. It has been cited 346 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph β no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full β never from an abstract alone.
Base Score Contribution
0.877
From this paper's citation signal
Citation Network Contribution
4.1
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) β log1p(Cq) divided by its reference count β out of 200 citers.
FWCI
7.08
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Loss of TET2 impairs endothelial angiogenesis via downregulating STAT3 target genes
Additional file 1 of Loss of TET2 impairs endothelial angiogenesis via downregulating STAT3 target genes
Additional file 2 of Loss of TET2 impairs endothelial angiogenesis via downregulating STAT3 target genes
Additional file 2 of Loss of TET2 impairs endothelial angiogenesis via downregulating STAT3 target genes
Additional file 2 of Ξ²-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo
Additional file 2 of Ξ²-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo
Additional file 1 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 1 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 3 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 3 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 4 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 4 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 5 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 5 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 6 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 6 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 7 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 7 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 8 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications
Additional file 8 of Dysregulated RNA editing of EIF2AK2 in polycystic ovary syndrome: clinical relevance and functional implications